Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 4, Issue 11, Pages 1069-1073Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml400267q
Keywords
Withalongolide A; withaferin A; triacetate; jaborosalactone; macrocycle; DRO81-1
Categories
Funding
- Office of Research and Graduate Studies, University of Kansas
- Mitscher Fellowship, University of Kansas
- Kansas Bioscience Authority (KBA) [IND 0061464]
- Center for Heartland Plant Innovations (HPI)
- Institute for Advancing Medical Innovation (IAMI) [NFP0066367]
- Department of Surgery at the University of Kansas Medical Center
- Department of Surgery at the University of Michigan
- University of Kansas Center for Cancer Experimental Therapeutics NIH-COBRE [P20 RR015563]
Ask authors/readers for more resources
The natural product withaferin A exhibits potent antitumor activity and other diverse pharmacological activities. The recently discovered withalongolide A, a C-19 hydroxylated congener of withaferin A, was recently reported to possess cytotoxic activity against head and neck squamous cell carcinomas. Semisynthetic acetylated analogues of withalongolide A were shown to be considerably more cytotoxic than the parent compound. To further explore the structure activity relationships, 20 new semisynthetic analogues of withalongolide A were synthesized and evaluated for cytotoxic activity against four different cancer cell lines. A number of derivatives were found to be more potent than the parent compound and withaferin A.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available